10112
| A prospective, randomized multicenter, multinational, double-blinded placebo controlled comparison of chemotherapy plus trastuzumab and placebo given for a total of one year versus chemotherapy plus trastuzumab and pertuzumab given for a total of one year as adjuvant therapy in patients with operable HER2-positive primary breast Cancer. |
10085
| Clinical and biological characterization of Male Breast Cancer : an international retrospective EORTC, BIG and NABCG intergroup study. |
22085
| A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast. |
10071
| A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer |
10055
| Phase III Trial Evaluating the role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (age 66 year or older) with Endocrine Non-responsive Breast Cancer who are NOT suitable for being Offered a "Standard Chemotherapy Regimen". |
10054
| A phase I-II study of Lapatinib and Docetaxel as neoadjuvant treatment for locally advanced breast cancer. |
10041
| MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid Chemo Therapy): A prospective, randomized study comparing the 70-gene signature with the common clinicpathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes" |
10053
| Pharmacokinetics study of combined treatment Lapatinib and Tamoxifen in advanced/metastatic breast cancer |
22051
| Selective Use of Postoperative Radiotherapy AftEr MastectOmy (SUPREMO) |
10031
| A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (SOFT). |
10021
| An EORTC randomized, double blind, placebo controlled, Phase II multi-center trial of anastrozole (Arimidex) in combination with ZD1839 (Irissa(R)) or placebo in patients with advanced breast cancer. |
10002
| A survey of the Breast International Group (B.I.G.) to assess the attitude of patients aged less than 35 years, with early breast cancer, toward the risk of loss of fertility related to adjuvant therapies. |
10001
| A randomized phase II-III trial evaluating the efficacy of capecitabine and vinorelbine in anthracycline and taxane pre-treated metastatic breast cancer.
|
10011
| A Randomized, Three-arm, Multicenter Comparison of 1 year and 2 years of
Herceptin Versus no Herceptin in Women with HER2 Positive Primary Breast
Cancer who have Completed Adjuvant Chemotherapy. |
10995
| A Phase II Study of CMF in Combination with Anti c-erbB2 antibody (HerceptinR) in Women with c-erbB2 positive Metastatic Breast Cancer |
10974
| LAMANOMA: Conservative local treatment versus mastectomy after induction
chemotherapy in locally advanced breast cancer: a randomized phase III study. |
10994
| First prospective Intergroup Translational Research Trial assessing
the potential predictive value of p53 using a functional assay in yeast
in patients with locally advanced/inflammatory or large operable breast cancer
prospectively randomised to a taxane versus a non taxane regimen. |
10981
| After Mapping of the Axilla:Radiotherapy Or Surgery
AMAROS |
10963
| PEAT-Perioperative Endocrine Adjuvant Treatment-
"A double blind phase III clinical trial to compare the effects of a preoperatively administered single dose of "Faslodex" (long acting ICI 182.780) with placebo on tumor recurrence in pre- and postmenopausal women treated for operable first primary cancer" |
10992
| Habits Hormonal replacement therapy after breast cancer diagnosis - is it safe? Protocol for randomized clinical study concerning hormonal replacement therapy (HRT) after previous radical breast cancer treatment. |
10983
| A Phase III randomized double blind study of letrozole versus placebo
in women with primary breast cancer completing five or more years
of adjuvant Tamoxifen (NCIC CTG MA.17, EORTC study 10983) |
16001
| Phase II study of oxaliplatin single agent in patients with metastatics breast
cancer after failure of Anthracycline/Taxanes based chemotherapy.
EORTC protocol 16001.
|
10993
| A randomised phase II study of two different schedules of Caelyx in metastatic
breast cancer
|
10967
| Randomized double-blind trial in postmenopausal women with primary breast cancer
who have received adjuvant Tamoxifen for 2-3 years, comparing subsequent adjuvant
Exemestane treatment with further Tamoxifen. |
10961
| Doxorubicin / Taxol as first line chemotherapy in advanced breast cancer : a randomized study versus standard Doxorubicin / Cyclophosphamide combination regimen. A phase II study leading to a phase III. |
22922
| Phase III randomized trial investigating the role of internal mammary and medial
supraclavicular (IM-MS) lymph node chain irradiation in stage I-III breast cancer
(Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group
EORTC 22922/10925) |
10951
| Randomized phase II and III study in first line hormonal treatment for metastatic breast
cancer with Exemestane or Tamoxifen in postmenopausal patients |
10932
| Phase III study of evaluation of breast irradiation in early stage, low risk breast cancer patients after complete tumor excision (Joint study of the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Cooperative Group) |
10941
| Open, non-randomized parallel-group, phase II study of Liarozole Fumarate in patients with advanced breast cancer |
10924
| Double-blind randomized phase III multicentre trial comparing the effect of oral pamidronate (CGP 23339A - Aredia) with placebo in patients with newly diagnosed bone metastases from breast cancer |
10920
| An EORTC randomized phase III trial aiming at defining the role of short-term intensive chemotherapy at the time of isolated loco-regional relapse in breast cancer patients |
10923
| Taxol versus Doxorubicin as first line chemotherapy in advanced breast cancer: A randomized phase II study with crossover |
10921
| A multicentre randomized phase III study of dose-intensive chemotherapy as primary treatment in a multimodality approach for locally advanced inflammatory breast cancer |
10922
| A phase II second line chemotherapy study with taxotere (RP56976) given as a one-hour infusion day 1, day 8 repeated every 3 weeks in patients with breast carcinoma |
10912
| Open phase II study of the nonsteroidal aromatase inhibitor, R 83 842 in postmenopausal women with advanced breast cancer (second line treatment). |
10901
| Randomized phase III study of adjuvant chemotherapy followed by adjuvant Tamoxifen versus nil for patients with operable breast cancer |
10902
| Randomized phase III study comparing short, intensive preoperative combination chemotherapy with similar therapy given post-operatively |
22881
| Phase III study in the conservative management of breast carcinoma by tumorectomy and radiotherapy: assessment of the role of a booster dose of radiotherapy (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group) |
10832
| Phase III trial on the comparison between the alternative and sequential
administration of three non-cross-resistant chemotherapy regimens ( CMF, ADM-DBD, CDDP-VDS ), in combination
with Tamoxifen in advanced breast cancer. |
10881
| Randomized phase III study of LHRH-agonist versus LHRH-agonist plus Tamoxifen versus Tamoxifen alone in the treatment of premenopausal advanced breast cancer |
10873
| Phase II trial of breast conserving therapy in women with Paget's disease of the nipple |
10872
| A PREVENTION TRIAL OF Tamoxifen IN WOMEN WITH LOBULAR CARCINOMA IN SITU (LCIS) OF THE BREAST. |
10871
| A RANDOMIZED PHASE II TRIAL OF Doxorubicin IN DIFFERENT DOSAGES AND SCHEDULES FOR ADVANCED BREAST CANCER, USED IN SECOND LINE IN CMF REFRACTORY PATIENTS. |
10863
| Phase III study of continuous Tamoxifen versus intermittent Tamoxifen versus alternating Tamoxifen and MPA. First line endocrine therapy for postmenopausal patients with advanced breast cancer. |
10861
| Randomized phase III trial of second line endocrine treatment of postmenopausal patients with advanced breast cancer |
10854
| Phase III trial of perioperative adjuvant chemotherapy in Breast Cancer |
10853
| Phase III trial of radiation therapy vs no treatment for patients with in situ ductal carcinoma of the breast (Jointly with the EORTC Radiotherapy Cooperative Group) |
10852
| Phase III trial of short versus long term chemotherapy with CMF in postmenopausal patients with advanced breast cancer. |
10850
| PHASE III TRIAL ON OPERABLE BREAST CANCER IN THE ELDERLY. TUMOR EXCISION PLUS Tamoxifen COMPARED WITH RADICAL MASTECTOMY |
10851
| PHASE III TRIAL ON OPERABLE BREAST CANCER IN THE ELDERLY: Tamoxifen ALONE COMPARED WITH MODIFIED RADICAL MASTECTOMY |
10761
| Phase III trial of postoperative CMF (cyclophosphamide/methotrexate/5-FU) plus levamisole or placebo in N+ primary breast cancer |
10804
| Phase II trial of 9-hydroxy-2N-methyl ellipticinium in advanced breast cancer |
10805
| Phase II trial of carminomycin and adriamycin in advanced breast cancer |
10806
| Phase II trial of AZQ in advanced breast cancer |
10811
| Phase II-III trial of 4'epi-adriamycin vs adriamycin in advanced breast cancer |
10821
| Pilot study on long-term preoperative chemotherapy in high risk breast cancer |
10833
| Randomized phase II trial of mitoxantrone and adriamycin for advanced breast cancer |
10807
| Phase II trial for the assessment of cyclic combination chemotherapy with estrogenic recruitment in advanced breast cancer |
10808
| Phase III trial of classical CMF versus three-monthly intravenous CMF in postmenopausal patients with advanced breast cancer |
10762
| Phase III trial of CMF versus CMF-TAM (tamoxifen)in postmenopausal women with advanced breast cancer |
10791
| Phase II trial of PALA in advanced breast cancer |
10792
| Phase III trial to assess the contribution of cytotoxic chemotherapy (CMF) and/or endocrine therapy (prednisolone/tamoxifen) to the primary treatment by radiotherapy of locally advanced breast cancer |
10801
| Phase III trial comparing mastectomy to tumorectomy |
10802
| Phase III trial of low dose versus high dose MPA (medroxyprogesterone acetate) in advanced breast cancer |
10803
| Phase II trial of cisplatin plus vindesine in advanced breast cancer |
10834
| Phase II trial on second line endocrine treatment of postmenopausal patients with advanced breast cancer |
10771BB
| Long-term CMF versus nothing in patients with axillary metastases, who having initially undergone (modified) radical mastectomy, received local radiotherapy
|
10891
| Phase III trial for the prevention of clinically manifest bone metastases with supportive oral APD therapy in patients with extra-skeletal distant breast cancer metastases. A placebo controlled double-blind randomized study. |
10742
| Tamoxifen in premenopausal patients with advanced breast cancer |
10741
| Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer |
10743
| Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer (excluded from 10741) |
10751
| Evaluation of a post-surgical alternating cyclical hormonal-cytotoxic therapy for patients with primary breast cancer of poor prognosis |
t10041
| |
